180 Life Sciences Corp. amended its previous filing to include details about the approval of the conversion of 1,000,000 Series B Convertible Preferred Stock into 1,813,000 common shares, granting significant voting rights to Elray Resources, Inc., which now holds 36.3% of the voting shares; additionally, the company approved a plan to increase shares available under its incentive plan from 223,679 to 1,000,000 shares.